Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06903923 · ClinicalTrials.gov registry record
Bone Metabolism in 12-21 Year Olds Undergoing GLP-1 Receptor Agonist Therapy
A clinical trial of Obesity and Bone Density, sponsored by University of Virginia.
- Recruiting
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT06903923: Recruiting study of Obesity and Bone Density, sponsored by University of Virginia.
NCT06903923 is a study of Obesity and Bone Density that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 120 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06903923, a study of Obesity and Bone Density, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to compare bone health markers over 24 months in participants 12 - 21 years of age with obesity who are starting the glucagon-like peptide-1 (GLP-1) Semaglutide as compared to those with similar weight followed by lifestyle management. Participants will: * Take Semaglutide as prescribed or continue to work on lifestyle management for weight loss * Take provided calcium and vitamin D supplements * Attend 6 study visits over 24 months with two at the beginning and then every 6 months that include: * History and Physical Exams * Lab Work * Imaging studies * Questionnaires * 24-hour dietary recalls * Mixed Meal Tolerance Test with a nutritional energy drink and six blood draws
Primary Outcome
Using repeated measures analysis, the investigators will compare change in radius vBMD after 24 months of treatment with GLP-1 RAs vs. routine care
Conditions Studied
Interventions
- BEHAVIORAL Lifestyle Management
- DRUG GLP-1 receptor agonist
Study Locations (1)
Virginia
- University of Virginia Medical Center - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-06-01 |
| Est. Completion | 2031-06-01 |
What NCT06903923 shows while recruiting
NCT06903923 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (85% lower).
The record links to 6 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Lifestyle Management is the first listed.
NCT06903923 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06903923 about?
NCT06903923 is a clinical study titled "Bone Metabolism in 12-21 Year Olds Undergoing GLP-1 Receptor Agonist Therapy". The goal of this clinical trial is to compare bone health markers over 24 months in participants 12 - 21 years of age with obesity who are starting the glucagon-like peptide-1 (GLP-1) Semaglutide as compared to those with similar weight followed by lifestyle management. Participants will: * Take S...
What is the current status of trial NCT06903923?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2025-06-01. Estimated completion is 2031-06-01.
What conditions does trial NCT06903923 study?
This clinical trial studies the following conditions: Obesity, Bone Density, GLP-1, Lifestyle Modification, Obesity in Children.
What interventions are being tested in trial NCT06903923?
The interventions under investigation include: Lifestyle Management (BEHAVIORAL), GLP-1 receptor agonist (DRUG).
Who is sponsoring clinical trial NCT06903923?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06903923 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06903923's enrollment target sits among peer trials
120 434th of 1053 higher than 607 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Tai Chi as a Novel Strategy to Increase Physical Activity Among Adults Pursuing Metabolic and Bariatric Surgery
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI